Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10932723 | 0.78 | KIF11 (0.54) | KIF11KCNN4TSHRALDH1A1CYP11B1 | |
| SCHEMBL28873040 | 0.75 | KIF11 (0.50) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL1149158 | 0.75 | KIF11 (0.64) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL1030653 | 0.74 | KIF11 (0.61) | KIF11CYP11B1CYP11B2CYP2C9CYP2C19 | |
| SCHEMBL17151091 | 0.71 | TSHR (0.48) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL7094449 | 0.71 | KIF11 (0.46) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL9319485 | 0.71 | KIF11 (0.46) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL913404 | 0.71 | KIF11 (0.46) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL766983 | 0.71 | KIF11 (0.46) | KIF11KCNN4TSHRALDH1A1TAAR1 | |
| SCHEMBL1971090 | 0.71 | KCNN4 (0.48) | KIF11KCNN4TSHRALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655457-A | Method for preparing resorcinol | 万华化学集团股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116655457-A | Method for preparing resorcinol | 万华化学集团股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20150080581-A1 | MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS | RIMTEC CORPORATION (JP) | 2015-03-19 | — | — | US | disclosed |
| US-8927670-B2 | Multicoordinated metal complexes for use in metathesis reactions | RIMTEC CORPORATION (JP) | 2015-01-06 | — | — | US | disclosed |
| EP-2397475-B1 | 4, 4' disubstituted 4H-cyclopentadithiophene and new methods for synthesising the same | IMEC (BE) | 2014-11-12 | — | — | EP | disclosed |
| US-8765882-B2 | Polythiophene based active layer for solar cells | IMEC (BE) | 2014-07-01 | — | — | US | disclosed |
| US-8698086-B2 | High effective atomic number polymer scintillators for gamma ray spectroscopy | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8450604-B2 | Polymerisable compounds for making opto-electronic devices | IMEC (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8329923-B2 | 4, 4′ disubstituted 4H-cyclopentadithiophene and new methods for synthesizing the same | IMEC (BE) | 2012-12-11 | — | — | US | disclosed |
| US-20120279569-A1 | POLYTHIOPHENE BASED ACTIVE LAYER FOR SOLAR CELLS | UNIVERSITEIT HASSELT (BE) | 2012-11-08 | — | — | US | disclosed |
| US-20080293905-A9 | MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS | RIMTEC CORPORATION (JP) | 2008-11-27 | — | — | US | disclosed |
| WO-2007022945-A2 | MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS | VIACATT N.V. (BE) | 2007-03-01 | — | — | WO | disclosed |
| EP-1757613-A1 | Multicoordinated metal complexes for use in metathesis reactions | Viacatt N.V. (BE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070043188-A1 | MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS | TELENE S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-6624116-B1 | Co-feeding a volatile Group 8B metal compound and/or a volatile promoter compound with the paraffinic hydrocarbon and oxygen feedstream into the oxidation reactor under ignition or autothermal process conditions | DOW GLOBAL TECHNOLOGIES INC. | 2003-09-23 | — | — | US | disclosed |
| EP-1114013-B1 | ON-LINE SYNTHESIS AND REGENERATION OF A CATALYST USED IN AUTOTHERMAL OXIDATION | DOW CHEMICAL CO (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1114013-A1 | ON-LINE SYNTHESIS AND REGENERATION OF A CATALYST USED IN AUTOTHERMAL OXIDATION | THE DOW CHEMICAL COMPANY (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6166283-A | On-line synthesis and regenerating of a catalyst used in autothermal oxidation | THE DOW CHEMICAL COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000014037-A1 | ON-LINE SYNTHESIS AND REGENERATION OF A CATALYST USED IN AUTOTHERMAL OXIDATION | THE DOW CHEMICAL COMPANY (US) | 2000-03-16 | — | — | WO | disclosed |
| US-4547320-A | ANTITUMOR AGENTS | NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK (NL) | 1985-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080581-A1 | MULTICOORDINATED METAL COMPLEXES FOR USE IN METATHESIS REACTIONS | APEX1, SOD1, AP1M1 | KIF11 2188/4885KCNN4 1023/4885TSHR 4417/4885 |
| US-20120279569-A1 | POLYTHIOPHENE BASED ACTIVE LAYER FOR SOLAR CELLS | SCO2, CLTB, CLTC | KIF11 3448/4885KCNN4 124/4885TSHR 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.